TargetUbiquitin carboxyl-terminal hydrolase 21(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human GST-tagged USP21 CD (196 to 565 residues) expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 21(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.66E+4nMAssay Description:Inhibition of core catalytic domain of USP21 (unknown origin) using ubiquitin-Rh110 as substrateMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 21(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >3.10E+4nMAssay Description:Inhibition of human USP21 using Ub-rhodamine 110 as substrateMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 21(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >3.10E+4nMAssay Description:Inhibition of human USP21 using Ub-rhodamine 110 as substrateMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 21(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >3.10E+4nMAssay Description:Inhibition of human USP21 using Ub-rhodamine 110 as substrateMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 21(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >3.10E+4nMAssay Description:Inhibition of human USP21 using Ub-rhodamine 110 as substrateMore data for this Ligand-Target Pair